Literature DB >> 3998050

Methodologic problems in clinical trials in heart failure.

G H Guyatt.   

Abstract

Trials designed to establish the effectiveness of pharmacologic therapy in chronic heart failure illustrate methodologic problems associated with intervention trials in chronic disease. Early improvement in hemodynamic status or exercise capacity does not predict long-term changes, and hemodynamic variables do not correlate with exercise capacity. Mortality may not be a feasible outcome, suggesting that an adequate measure of quality of life is necessary to establish patient benefit. Care must be taken to ensure that subjects recruited are representative of the underlying population with respect to drug response. Need for cointervention can be dealt with by comparing only periods of comparable treatment, treating need for cointervention as a treatment failure, or using changes in non-study drugs as a measure of outcome. While cross-over designs can improve feasibility, the investigator runs the risk of inadequate followup and a time-treatment interaction. These issues must be considered in planning intervention trials in chronic disease.

Entities:  

Mesh:

Year:  1985        PMID: 3998050     DOI: 10.1016/0021-9681(85)90081-5

Source DB:  PubMed          Journal:  J Chronic Dis        ISSN: 0021-9681


  10 in total

Review 1.  Centrally acting sympatholytic agents in the treatment of congestive heart failure. A review of the literature.

Authors:  A Manmontri; S M MacLeod
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

2.  Classification of heart failure in population based research: an assessment of six heart failure scores.

Authors:  A Mosterd; J W Deckers; A W Hoes; A Nederpel; A Smeets; D T Linker; D E Grobbee
Journal:  Eur J Epidemiol       Date:  1997-07       Impact factor: 8.082

3.  CNS-related subjective symptoms during treatment with beta 1-adrenoceptor antagonists (atenolol, metoprolol): two double-blind placebo controlled studies.

Authors:  E Dimenäs; C Dahlöf; B Olofsson; I Wiklund
Journal:  Br J Clin Pharmacol       Date:  1989-11       Impact factor: 4.335

4.  Measurement of the quality of life in congestive heart failure-Influence of drug therapy.

Authors:  Christopher J Bulpitt; Astrid E Fletcher
Journal:  Cardiovasc Drugs Ther       Date:  1988-11       Impact factor: 3.727

5.  How do changes in lifestyle complement medical treatment in heart failure?

Authors:  J Soler-Soler; G Permanyer-Miralda
Journal:  Br Heart J       Date:  1994-09

Review 6.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

Review 7.  A review of quality-of-life evaluations in patients with congestive heart failure.

Authors:  C Berry; J McMurray
Journal:  Pharmacoeconomics       Date:  1999-09       Impact factor: 4.981

8.  Development and testing of a new measure of health status for clinical trials in heart failure.

Authors:  G H Guyatt; S Nogradi; S Halcrow; J Singer; M J Sullivan; E L Fallen
Journal:  J Gen Intern Med       Date:  1989 Mar-Apr       Impact factor: 5.128

9.  Methods for assessing quality of life in the cardiac arrhythmia suppression trial (CAST).

Authors:  I Willund; L Gorkin; Y Pawitan; E Schron; J Schoenberger; L L Jared; S Shumaker
Journal:  Qual Life Res       Date:  1992-06       Impact factor: 4.147

Review 10.  Why different trials on digitalis give conflicting data.

Authors:  R Jaeschke; G H Guyatt
Journal:  Cardiovasc Drugs Ther       Date:  1989-01       Impact factor: 3.727

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.